ClinicalTrials.gg
CompletedNCT06033547Updated Feb 6, 2026

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

A Phase 1 interventional study of Cabotegravir Formulation F and Cabotegravir Formulation G in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
122nd of 210
56 · median 82
Started
2023
with 9 others
Phase 1
83 of 266
9 open now
Registered
240th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 122nd largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2023, is one of 83 in phase 1, and was the 240th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult participants. The study will initially start with the assessment of Cabotegravir Formulation F. Once the clinical batch of Cabotegravir Formulation G is available, this formulation will be assessed.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Body weight =>40 kilogram (kg) and (BMI) within the range =>18 to =\<32 kilogram per meter square (kg/m\^2)
  • Participants who are negative on a single test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(approved molecular polymerase chain reaction [PCR] laboratory or point of care test) performed on the day of admission. A negative result is required prior to the administration of study intervention on Day 1.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Participants assigned female at birth are eligible to participate if they are not pregnant or breastfeeding, and at least one of the following conditions applies:
  • Is not a woman of (WOCBP) OR
  • Is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of \<1% from the time of screening and inclusive of the entire time while on the study.
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the 30 days before the first dose of study intervention.
  • Capable of giving written

Exclusion criteria

Exclusion Criteria:

  • Current presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities.
  • History of ongoing or seizure disorder within the previous 2 years, including participants who have required treatment for seizures within this time period.
  • Participants who in the investigator's judgment, poses a significant suicidality risk. Participant's history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
  • Positive SARS-CoV-2 polymerase chain reaction test, having signs and symptoms which in the opinion of the investigator are suggestive of COVID-19 (i.e., fever, cough etc) within 14 days of inpatient admission, or having contact with known COVID-19 positive person/s in the 14 days prior to inpatient admission.
  • (HIV-1 or HIV-2) infection as indicated by positive antibody/antigen test.
  • History of or on-going high-risk behaviors that, in the opinion of the investigator, may put the participant at increased risk for HIV infection including, but not limited to, participants in HIV discordant relationships, or men who report current or prior unprotected anal sex with other men and those reporting prior or current injecting drug use.
  • Presence of surface antigen (HBsAg), or positive antibody test result at screening or within 3 months prior to first dose of study treatment.
  • Abnormal blood pressure.
  • Evidence of previous myocardial infarction.
  • Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular [AV] block [2nd degree or higher], Wolff- Parkinson-White [WPW] syndrome).
  • Any significant arrhythmia which, in the opinion of the investigator or the medical monitor, will interfere with the safety for the individual participant.
  • One or more exclusionary values for a screening (ECG).
  • (ALT) >1.5x (ULN).
  • >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]).
  • Estimated (eGFR) \<60 milliliter per minute (mL/min) using the Chronic Kidney Disease - Improved Prediction Equations (CKD-EPI) Creatinine Equation (2021).
  • \<12.5 gram per deciliter (g/dL) for men and \<11 g/dL for women.
  • Positive pre-study drug/alcohol screen.
  • Regular use of tobacco- or nicotine-containing products within 3 months prior to screening; or urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (e.g., nicotine patches or vaporizing devices).
  • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >14 units for males or >7 units for females.
  • Regular use of known drugs of abuse.
  • Concurrent participation in another clinical trial (except imaging trials); or has participated in a clinical trial and received an product within the following time period prior to the first dosing day in this study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Participation in the study would result in loss of blood or blood products in excess of 500 mL within 56 days.
  • Exposure to more than four (4) new chemical entities within 12 months prior to the first dosing day.
  • History of sensitivity to any of the study interventions (or components thereof), a history of drug allergy or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation
  • Current or anticipated need for chronic anti-coagulation therapy (with the exception of low-dose aspirin =\< 325 mg/day)
  • Hereditary coagulation and disorders (e.g., haemophilia or Von Willebrand disease [VWD]).
  • Participant has a tattoo overlying the location of injection or an underlying skin disease or condition (e.g., infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) that, in the opinion of the investigator, may interfere with interpretation of injection site reactions or administration of study intervention.
  • Any other clinical condition, behaviour or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part A: Participants receiving Cabotegravir Formulation F

    Drug: Cabotegravir Formulation F

  • Experimental
    Part B: Participants receiving Cabotegravir Formulation G

    Drug: Cabotegravir Formulation G

Interventions

  • DrugCabotegravir Formulation F

    Cabotegravir Formulation F will be administered

  • DrugCabotegravir Formulation G

    Cabotegravir Formulation G will be administered

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of cabotegravir

    Time frame: Up to Week 52

  2. Time of maximum observed plasma concentration (tmax) of cabotegravir

    Time frame: Up to Week 52

  3. Area under the concentration - time curve from time zero to 4 weeks following the injection (AUC[0-4]) of cabotegravir

    Time frame: Up to Week 4

  4. Plasma Concentration of cabotegravir at Week 4

    Time frame: Week 4

  5. Number of participants with adverse events (AEs) based on severity

    Time frame: Up to Week 52

  6. Absolute value of haematology parameter: Platelet count (cells per microliter)

    Time frame: Up to Week 52

  7. Absolute value of haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)

    Time frame: Up to Week 52

  8. Absolute values of haematology parameters: haemoglobin (Hgb) (grams per decilitre)

    Time frame: Up to Week 52

  9. Absolute values of haematology parameters: haematocrit (Proportion of red blood cells in blood)

    Time frame: Up to Week 52

  10. Absolute value of haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)

    Time frame: Up to Week 52

  11. Absolute value of haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)

    Time frame: Up to Week 52

  12. Absolute values of haematology parameters: Reticulocytes (Percentage of reticulocytes)

    Time frame: Up to Week 52

  13. Absolute values of haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)

    Time frame: Up to Week 52

  14. Absolute values of Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)

    Time frame: Up to Week 52

  15. Absolute values of Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)

    Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed.

    Time frame: Up to Week 52

  16. Absolute values of Clinical chemistry parameters: Total Protein (Grams per deciliter)

    Time frame: Up to Week 52

  17. Absolute values of Clinical chemistry parameters: Estimated Glomerular Filtration Rate (eGFR2) (millilitres per minute)

    Time frame: Up to Week 52

  18. Change from Baseline in haematology parameter: Platelet count (cells per microliter)

    Time frame: Baseline (Day 1) and up to Week 52

  19. Change from Baseline in haematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)

    Time frame: Baseline (Day 1) and up to Week 52

  20. Change from baseline in haematology parameters: haematocrit (Proportion of red blood cells in blood)

    Time frame: Baseline (Day 1) and up to Week 52

  21. Change from baseline in haematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)

    Time frame: Baseline (Day 1) and up to Week 52

  22. Change from baseline in haematology parameter: Mean Corpuscle haemoglobin (MCH) (Picograms)

    Time frame: Baseline (Day 1) and up to Week 52

  23. Change from baseline in haematology parameters: Reticulocytes (Percentage of reticulocytes)

    Time frame: Baseline (Day 1) and up to Week 52

  24. Change from baseline in haematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)

    Time frame: Baseline (Day 1) and up to Week 52

  25. Change from baseline in Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per decilitre)

    Time frame: Baseline (Day 1) and up to Week 52

  26. Change from baseline in Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)

    Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed

    Time frame: Baseline (Day 1) and up to Week 52

  27. Change from baseline in Clinical chemistry parameters: Total Protein (Grams per deciliter)

    Time frame: Baseline (Day 1) and up to Week 52

  28. Change from baseline in Clinical chemistry parameters: Estimated Glomerular Filtration Rate (eGFR) (millilitres per minute)

    Time frame: Baseline (Day 1) and up to Week 52

Secondary outcomes

  1. Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of cabotegravir

    Time frame: Up to Week 52

  2. Area under the concentration - time curve from time zero to time of last quantifiable concentration [AUC(0-last)] of cabotegravir

    Time frame: Up to Week 52

  3. Plasma Concentration of cabotegravir at Week 8,12 and 24

    Time frame: Week 8, 12 and 24

  4. Apparent terminal phase half-life (t1/2) of cabotegravir

    Time frame: Up to Week 52

  5. Apparent long-acting absorption rate constant (KA-LA) of cabotegravir

    Time frame: Up to Week 52

  6. Dose proportionality of cabotegravir based on AUC(0-inf), AUC(0-last), Cmax, and plasma concentration (Unit of measure: Slope of log dose)

    Time frame: Up to Week 52

  7. Number of participants with maximum post-baseline QTc values compared to baseline by category (to <=450 milliseconds (msec) or no change, to >450 msec to <=480 msec, to >480 msec to <=500 msec, and to >500 msec)

    Time frame: Up to Week 52

  8. Number of participants with maximum post-baseline increase in QTc values compared to baseline based on category (increase <=30 msec, increase of 31-60 msec, and increase of >60 msec)

    Time frame: Up to Week 52

  9. Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate

    Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline will be categorized into change to low, change to within range or no change, and change to high

    Time frame: Up to Week 52

07

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jul 2025, 22 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 22 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 13, 2023
StartActual
Sep 12, 2023
Primary completionActual
Jul 25, 2025
CompletionActual
Jul 25, 2025
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06033547
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Sep 12, 2023
Primary completion
Jul 25, 2025
Completion
Jul 25, 2025
Last update
Feb 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion